Abstract
The beneficial effects of chronic exercise training on lipoprotein metabolism include a considerable increase in serum high density lipoprotein-cholesterol and a reduction in serum triglyceride levels. These changes are mostly reported in athletes participating in dynamic sports, especially in the endurance ones. Diagnosis and treatment of dyslipidaemias in athletes should follow the main principles of management of dyslipidaemias for the general population, while specific considerations for athletes should be taken into account. Dyslipidaemias in athletes are usually characterized by a significant genetic predisposition. Clinicians who evaluate the lipoprotein profile of athletes should keep in mind the possibility of an illegal use of performance-enhancing drugs, which can influence lipoprotein metabolism. Lifestyle intervention should be the cornerstone of treatment of dyslipidaemias in athletes, but it should be tailored to the needs of individual athletic activity. Hypolipidaemic medications may not be well-tolerated by competitive athletes and should be reserved only for athletes with inadequate response to lifestyle measures. The treatment of dyslipidaemias in athletes should aim at reducing cardiovascular risk without compromising athletic performance.
Keywords: Sports, dyslipidaemia, athletes, lipoproteins, high density lipoprotein-cholesterol, triglycerides.
Current Vascular Pharmacology
Title:Diagnosis and Treatment of Dyslipidaemias in Athletes
Volume: 15 Issue: 3
Author(s): Georgios A. Christou, Evangelia J. Kouidi, Asterios P. Deligiannis and Dimitrios N. Kiortsis*
Affiliation:
- Laboratory of Physiology, Medical School, University of Ioannina, 45110 Ioannina,Greece
Keywords: Sports, dyslipidaemia, athletes, lipoproteins, high density lipoprotein-cholesterol, triglycerides.
Abstract: The beneficial effects of chronic exercise training on lipoprotein metabolism include a considerable increase in serum high density lipoprotein-cholesterol and a reduction in serum triglyceride levels. These changes are mostly reported in athletes participating in dynamic sports, especially in the endurance ones. Diagnosis and treatment of dyslipidaemias in athletes should follow the main principles of management of dyslipidaemias for the general population, while specific considerations for athletes should be taken into account. Dyslipidaemias in athletes are usually characterized by a significant genetic predisposition. Clinicians who evaluate the lipoprotein profile of athletes should keep in mind the possibility of an illegal use of performance-enhancing drugs, which can influence lipoprotein metabolism. Lifestyle intervention should be the cornerstone of treatment of dyslipidaemias in athletes, but it should be tailored to the needs of individual athletic activity. Hypolipidaemic medications may not be well-tolerated by competitive athletes and should be reserved only for athletes with inadequate response to lifestyle measures. The treatment of dyslipidaemias in athletes should aim at reducing cardiovascular risk without compromising athletic performance.
Export Options
About this article
Cite this article as:
Christou A. Georgios, Kouidi J. Evangelia, Deligiannis P. Asterios and Kiortsis N. Dimitrios*, Diagnosis and Treatment of Dyslipidaemias in Athletes, Current Vascular Pharmacology 2017; 15 (3) . https://dx.doi.org/10.2174/1570161115666170127162526
DOI https://dx.doi.org/10.2174/1570161115666170127162526 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
"New Frontiers in Cardiovascular and Hematologic Disease Treatment: Exploring and Applying Natural Drug Targets"
Cardiovascular and hematologic diseases are among the most pressing global health challenges, placing a heavy burden on public health systems worldwide. As research progresses, novel therapeutic targets continue to be identified, offering new possibilities for treating these complex conditions. However, despite advancements in current therapies, more integrated research approaches are ...read more
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetic Complications: An Update on Pathobiology and Therapeutic
Strategies
Current Diabetes Reviews Management of Cardiovascular Risk Factors in Patients with Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Platelet Alpha- and Beta- Secretase Activities are not Significantly Affected by Dementia or Mild Cognitive Impairment in Swedish Patients
Current Alzheimer Research Receptor-Based 3D-QSAR Study for Recognizing True Binding Mode of Mercaptoacyldipeptides at the Active Site of Neutral Endopeptidase
Medicinal Chemistry MRI of the Small and Large Bowel
Current Medical Imaging Recent Advances in Synaptosomal Proteomics in Alzheimer’s Disease
Current Protein & Peptide Science Association of Dietary Prebiotic Consumption with Reduced Risk of Alzheimer’s Disease in a Multiethnic Population
Current Alzheimer Research Transient Receptor Potential Channels and Dermatological Disorders
Current Topics in Medicinal Chemistry Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS
Endocrine, Metabolic & Immune Disorders - Drug Targets Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Downregulation of GPR4 and TCF7 Promotes Apoptosis and Inhibits Growth and Invasion of Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Neurodegeneration and Glial Activation Related CSF Biomarker as the Diagnosis of Alzheimer’s Disease: A Systematic Review and an Updated Meta- analysis
Current Alzheimer Research Endocrine Disrupting Chemical Induced “Pollution of Metabolic Pathways”: A Case of Shifting Paradigms With Implications for Vascular Diseases
Current Drug Targets Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Effects of Thiazolidinediones on Coronary Artery Disease: Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Vitamin E - Occurrence, Biosynthesis by Plants and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Inevitable Role of Traditional Systems of Medicine in Managing Non-Communicable Diseases (NCD))
Current Traditional Medicine Aceruloplasminemia
Current Drug Targets Anti-Angiogenetic Agents from the Sea: A New Potential Preventive and Therapeutic Wave?
Anti-Cancer Agents in Medicinal Chemistry